Adaptimmune Therapeutics plc (ADAPY) Stock Price & Analysis
Adaptimmune Therapeutics plc (ADAPY) — price $0.03 (+27.66%), as of the Nov 19, 2026 trading session; market cap $7.95M.
Educational signal · not a buy or sell recommendation · How to read this
Adaptimmune Therapeutics plc · ADAPY
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing novel T-cell immunotherapies for cancer patients in the US and UK. Leveraging its genetically modified autologous T-cell platform, the company advances therapies like TECELRA for synovial sarcoma, alongside a pipeline targeting various cancers through strategic collaborations, positioning it in the specialized cell therapy market.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.03 | |
| Change on the day | +27.66% | |
| 52-week range | $0.001 – $0.07 | |
| Market capitalisation | $7.95M | — |
| Price / earnings (trailing) | 0.11 | |
| Shares traded on the day | 514.8K |
Price & events
Other perspectives
Council score for Adaptimmune Therapeutics (ADAPY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Adaptimmune Therapeutics (ADAPY), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Adaptimmune Therapeutics plc (ADAPY) is the company analyzed here. It employs 272 people and is led by Christopher James Hill. In Q1 FY2025 it reported revenue of $7M and net income of -$48M. The market values it at $7.95M.
What do the latest results show for Adaptimmune Therapeutics (ADAPY)?
Short answer · as of
The most recent reported quarter, Q1 FY2025, carried revenue of $7M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2025 | $7M | -$48M | -$0.19 (diluted) |
| Q2 FY2025 | $14M | -$30M | -$0.11 (diluted) |
What are the financial strengths and risks for Adaptimmune Therapeutics (ADAPY)?
Short answer · as of
The distress and quality screens read Altman Z -15.85 · Piotroski F 0. Trailing ratios: ROA -25.9% · current ratio 2.04.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -15.85 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
What should you watch next at Adaptimmune Therapeutics (ADAPY)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $20.70M · EPS -0.50 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q1 FY2025) was filed May 13, 2025 — 13 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $20.70M
- EPS estimate
- $-0.50
Measured against a quoted price of $0.03 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ADAPY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ADAPY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Adaptimmune Therapeutics (ADAPY)
These answers are editorial: 1 of these 8 answers is drawn from the ADAPY research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ADAPY a good stock to buy?
Stock Expert AI does not rate ADAPY buy, sell or hold. Adaptimmune Therapeutics plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ADAPY stock price today?
The last price recorded for Adaptimmune Therapeutics plc (ADAPY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the implications of Adaptimmune Therapeutics plc trading on the OTC market?
Trading on the "OTC Other" tier of the OTC market carries several implications for Adaptimmune Therapeutics plc and its investors.
What are the key factors to evaluate for ADAPY?
Evaluate ADAPY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does ADAPY data refresh on this page?
ADAPY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ADAPY's recent stock price performance?
Adaptimmune Therapeutics plc (ADAPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercial-stage product (TECELRA) addressing an unmet medical need in synovial sarcoma. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADAPY overvalued or undervalued right now?
The trailing P/E of Adaptimmune Therapeutics plc (ADAPY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ADAPY before investing?
Before investing in Adaptimmune Therapeutics plc (ADAPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP) and 8 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com